JP7371019B2 - 疾病の予後と管理のための方法 - Google Patents
疾病の予後と管理のための方法 Download PDFInfo
- Publication number
- JP7371019B2 JP7371019B2 JP2020563696A JP2020563696A JP7371019B2 JP 7371019 B2 JP7371019 B2 JP 7371019B2 JP 2020563696 A JP2020563696 A JP 2020563696A JP 2020563696 A JP2020563696 A JP 2020563696A JP 7371019 B2 JP7371019 B2 JP 7371019B2
- Authority
- JP
- Japan
- Prior art keywords
- als
- subject
- biomarker
- scd14
- patients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 92
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 65
- 201000010099 disease Diseases 0.000 title description 59
- 238000004393 prognosis Methods 0.000 title description 7
- 230000000750 progressive effect Effects 0.000 claims description 309
- 102000005482 Lipopolysaccharide Receptors Human genes 0.000 claims description 229
- 108010031801 Lipopolysaccharide Receptors Proteins 0.000 claims description 229
- 210000002966 serum Anatomy 0.000 claims description 184
- 239000000090 biomarker Substances 0.000 claims description 164
- 230000027455 binding Effects 0.000 claims description 87
- 239000000427 antigen Substances 0.000 claims description 74
- 108091007433 antigens Proteins 0.000 claims description 74
- 102000036639 antigens Human genes 0.000 claims description 74
- 239000012472 biological sample Substances 0.000 claims description 74
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 26
- 238000011282 treatment Methods 0.000 claims description 25
- 239000007787 solid Substances 0.000 claims description 22
- 238000011269 treatment regimen Methods 0.000 claims description 20
- 210000002700 urine Anatomy 0.000 claims description 16
- 230000007423 decrease Effects 0.000 claims description 14
- 210000004369 blood Anatomy 0.000 claims description 13
- 239000008280 blood Substances 0.000 claims description 13
- 239000011324 bead Substances 0.000 claims description 12
- 238000005259 measurement Methods 0.000 claims description 10
- 101000801254 Homo sapiens Tumor necrosis factor receptor superfamily member 16 Proteins 0.000 claims description 9
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 claims description 9
- 108091073532 miR-143 stem-loop Proteins 0.000 claims description 9
- 108091063796 miR-206 stem-loop Proteins 0.000 claims description 9
- 108091048101 miR-374b stem-loop Proteins 0.000 claims description 9
- 210000002381 plasma Anatomy 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 7
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 419
- 210000001616 monocyte Anatomy 0.000 description 129
- 102000052508 Lipopolysaccharide-binding protein Human genes 0.000 description 119
- 108010053632 Lipopolysaccharide-binding protein Proteins 0.000 description 119
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 96
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 95
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 58
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 58
- 230000001965 increasing effect Effects 0.000 description 58
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 57
- 230000005750 disease progression Effects 0.000 description 52
- 206010061818 Disease progression Diseases 0.000 description 51
- 108010074051 C-Reactive Protein Proteins 0.000 description 41
- 102100032752 C-reactive protein Human genes 0.000 description 41
- 230000003247 decreasing effect Effects 0.000 description 37
- 239000012634 fragment Substances 0.000 description 37
- 210000004027 cell Anatomy 0.000 description 35
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 29
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 29
- 230000014509 gene expression Effects 0.000 description 28
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 28
- 230000000770 proinflammatory effect Effects 0.000 description 25
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 24
- 208000037821 progressive disease Diseases 0.000 description 24
- 239000000523 sample Substances 0.000 description 24
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 23
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 23
- 239000003795 chemical substances by application Substances 0.000 description 22
- 238000012360 testing method Methods 0.000 description 22
- 239000002158 endotoxin Substances 0.000 description 21
- 208000024891 symptom Diseases 0.000 description 21
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 20
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 20
- 238000004458 analytical method Methods 0.000 description 20
- 108020004999 messenger RNA Proteins 0.000 description 20
- 230000035945 sensitivity Effects 0.000 description 20
- 229940123708 CD14 antagonist Drugs 0.000 description 19
- -1 kits Substances 0.000 description 18
- 239000000203 mixture Substances 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- 210000002540 macrophage Anatomy 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 230000002829 reductive effect Effects 0.000 description 17
- 230000004913 activation Effects 0.000 description 16
- 229920006008 lipopolysaccharide Polymers 0.000 description 16
- 239000000463 material Substances 0.000 description 16
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 15
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 15
- 230000002596 correlated effect Effects 0.000 description 15
- 102000005962 receptors Human genes 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- 206010012289 Dementia Diseases 0.000 description 11
- 108060003951 Immunoglobulin Proteins 0.000 description 11
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 102000018358 immunoglobulin Human genes 0.000 description 11
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 10
- 102100027581 Forkhead box protein P3 Human genes 0.000 description 10
- 201000011240 Frontotemporal dementia Diseases 0.000 description 10
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 10
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 210000003289 regulatory T cell Anatomy 0.000 description 10
- 238000013077 scoring method Methods 0.000 description 10
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 10
- 238000003745 diagnosis Methods 0.000 description 9
- 230000001404 mediated effect Effects 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 101150013553 CD40 gene Proteins 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 8
- 101000979333 Homo sapiens Neurofilament light polypeptide Proteins 0.000 description 8
- 102100023057 Neurofilament light polypeptide Human genes 0.000 description 8
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 8
- 230000002555 anti-neurodegenerative effect Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 230000015788 innate immune response Effects 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 230000007112 pro inflammatory response Effects 0.000 description 8
- 230000002250 progressing effect Effects 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 238000003491 array Methods 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 230000003834 intracellular effect Effects 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 208000015122 neurodegenerative disease Diseases 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 238000009423 ventilation Methods 0.000 description 7
- 208000024827 Alzheimer disease Diseases 0.000 description 6
- 208000012902 Nervous system disease Diseases 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 230000004770 neurodegeneration Effects 0.000 description 6
- 230000002093 peripheral effect Effects 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 241001529936 Murinae Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 208000025966 Neurological disease Diseases 0.000 description 5
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 5
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 5
- 102000008233 Toll-Like Receptor 4 Human genes 0.000 description 5
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical compound O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 description 5
- 229950009041 edaravone Drugs 0.000 description 5
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 5
- 229940072221 immunoglobulins Drugs 0.000 description 5
- 238000007726 management method Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 238000007837 multiplex assay Methods 0.000 description 5
- 210000005036 nerve Anatomy 0.000 description 5
- 210000000578 peripheral nerve Anatomy 0.000 description 5
- 210000001428 peripheral nervous system Anatomy 0.000 description 5
- 230000004202 respiratory function Effects 0.000 description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 4
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 4
- 108010029697 CD40 Ligand Proteins 0.000 description 4
- 102100032937 CD40 ligand Human genes 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 210000003494 hepatocyte Anatomy 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000002161 motor neuron Anatomy 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 3
- 102000000844 Cell Surface Receptors Human genes 0.000 description 3
- 108010001857 Cell Surface Receptors Proteins 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 101000935587 Homo sapiens Flavin reductase (NADPH) Proteins 0.000 description 3
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 3
- 239000002139 L01XE22 - Masitinib Substances 0.000 description 3
- 102100025136 Macrosialin Human genes 0.000 description 3
- VATFHFJULBPYLM-ILOBPARPSA-N PMX-205 Chemical compound C([C@@H]1C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@H](C(NCCC[C@@H](C(=O)N2CCC[C@H]2C(=O)N1)NC(=O)CCC=1C=CC=CC=1)=O)CCCN=C(N)N)C1CCCCC1 VATFHFJULBPYLM-ILOBPARPSA-N 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 102000002689 Toll-like receptor Human genes 0.000 description 3
- 108020000411 Toll-like receptor Proteins 0.000 description 3
- 230000033289 adaptive immune response Effects 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000024203 complement activation Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 229960002224 eculizumab Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 108010011646 hydrocinnamate-cyclo(ornithyl-prolyl-cyclohexylalanyl-tryptophyl-arginyl) Proteins 0.000 description 3
- 230000005934 immune activation Effects 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 210000002074 inflammatory monocyte Anatomy 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- WJEOLQLKVOPQFV-UHFFFAOYSA-N masitinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3SC=C(N=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 WJEOLQLKVOPQFV-UHFFFAOYSA-N 0.000 description 3
- 229960004655 masitinib Drugs 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 238000000554 physical therapy Methods 0.000 description 3
- 230000006337 proteolytic cleavage Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 229960004181 riluzole Drugs 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 102100032814 ATP-dependent zinc metalloprotease YME1L1 Human genes 0.000 description 2
- 208000000187 Abnormal Reflex Diseases 0.000 description 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000010170 Death domains Human genes 0.000 description 2
- 108050001718 Death domains Proteins 0.000 description 2
- 208000019505 Deglutition disease Diseases 0.000 description 2
- 206010013887 Dysarthria Diseases 0.000 description 2
- 208000004929 Facial Paralysis Diseases 0.000 description 2
- 108010008177 Fd immunoglobulins Proteins 0.000 description 2
- 206010017577 Gait disturbance Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 2
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 102100022338 Integrin alpha-M Human genes 0.000 description 2
- 108010048043 Macrophage Migration-Inhibitory Factors Proteins 0.000 description 2
- 102100037791 Macrophage migration inhibitory factor Human genes 0.000 description 2
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 2
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 208000008238 Muscle Spasticity Diseases 0.000 description 2
- 206010028289 Muscle atrophy Diseases 0.000 description 2
- 108010083674 Myelin Proteins Proteins 0.000 description 2
- 102000006386 Myelin Proteins Human genes 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 101800000795 Proadrenomedullin N-20 terminal peptide Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 101150033483 Slbp gene Proteins 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 208000036826 VIIth nerve paralysis Diseases 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 101100365875 Xenopus laevis slbp1 gene Proteins 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 108010073240 complement C5a-inhibitors Proteins 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000013211 curve analysis Methods 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 210000001808 exosome Anatomy 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 206010020745 hyperreflexia Diseases 0.000 description 2
- 230000035859 hyperreflexia Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000005007 innate immune system Anatomy 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 208000027906 leg weakness Diseases 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000013178 mathematical model Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 239000011325 microbead Substances 0.000 description 2
- 210000000274 microglia Anatomy 0.000 description 2
- 230000002025 microglial effect Effects 0.000 description 2
- 230000020763 muscle atrophy Effects 0.000 description 2
- 201000000585 muscular atrophy Diseases 0.000 description 2
- 210000005012 myelin Anatomy 0.000 description 2
- 210000000066 myeloid cell Anatomy 0.000 description 2
- 230000000626 neurodegenerative effect Effects 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000001584 occupational therapy Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000001671 psychotherapy Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 208000026473 slurred speech Diseases 0.000 description 2
- 208000018198 spasticity Diseases 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000002630 speech therapy Methods 0.000 description 2
- 238000013517 stratification Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 101150053137 AIF1 gene Proteins 0.000 description 1
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 description 1
- 102000005590 Anaphylatoxin C5a Receptor Human genes 0.000 description 1
- 108010059426 Anaphylatoxin C5a Receptor Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 229940110394 C5a inhibitor Drugs 0.000 description 1
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 241000251556 Chordata Species 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 1
- 102100026846 Cytidine deaminase Human genes 0.000 description 1
- 108010031325 Cytidine deaminase Proteins 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010040721 Flagellin Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 description 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 1
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
- 101001111338 Homo sapiens Neurofilament heavy polypeptide Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 208000026072 Motor neurone disease Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 1
- 102100024007 Neurofilament heavy polypeptide Human genes 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 102000017794 Perilipin-2 Human genes 0.000 description 1
- 108010067163 Perilipin-2 Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 1
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000011256 aggressive treatment Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000007792 alzheimer disease pathology Effects 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 102000025171 antigen binding proteins Human genes 0.000 description 1
- 108091000831 antigen binding proteins Proteins 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000012468 concentrated sample Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 206010061811 demyelinating polyneuropathy Diseases 0.000 description 1
- 230000002638 denervation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000000104 diagnostic biomarker Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000021196 dietary intervention Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000001097 direct analysis in real time mass spectrometry Methods 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 102000046699 human CD14 Human genes 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 238000005399 mechanical ventilation Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000023881 membrane protein ectodomain proteolysis Effects 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 208000018731 motor weakness Diseases 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000001703 neuroimmune Effects 0.000 description 1
- 238000010984 neurological examination Methods 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- PIRWNASAJNPKHT-SHZATDIYSA-N pamp Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)N)C(C)C)C1=CC=CC=C1 PIRWNASAJNPKHT-SHZATDIYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000007414 peripheral immune response Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000092 prognostic biomarker Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940072169 rilutek Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000004116 schwann cell Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 239000004054 semiconductor nanocrystal Substances 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 230000008718 systemic inflammatory response Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023179310A JP2023181255A (ja) | 2018-05-10 | 2023-10-18 | 疾病の予後と管理のための方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862669915P | 2018-05-10 | 2018-05-10 | |
| US62/669,915 | 2018-05-10 | ||
| PCT/US2019/031858 WO2019217916A1 (en) | 2018-05-10 | 2019-05-10 | Methods for prognosis and management of disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023179310A Division JP2023181255A (ja) | 2018-05-10 | 2023-10-18 | 疾病の予後と管理のための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021523375A JP2021523375A (ja) | 2021-09-02 |
| JP2021523375A5 JP2021523375A5 (https=) | 2022-05-18 |
| JP7371019B2 true JP7371019B2 (ja) | 2023-10-30 |
Family
ID=66655475
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020563696A Active JP7371019B2 (ja) | 2018-05-10 | 2019-05-10 | 疾病の予後と管理のための方法 |
| JP2023179310A Pending JP2023181255A (ja) | 2018-05-10 | 2023-10-18 | 疾病の予後と管理のための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023179310A Pending JP2023181255A (ja) | 2018-05-10 | 2023-10-18 | 疾病の予後と管理のための方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20210231686A1 (https=) |
| EP (1) | EP3791188A1 (https=) |
| JP (2) | JP7371019B2 (https=) |
| KR (1) | KR20210014109A (https=) |
| CN (1) | CN112424608A (https=) |
| AU (1) | AU2019264996A1 (https=) |
| IL (1) | IL278616B2 (https=) |
| WO (1) | WO2019217916A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL309046B2 (en) | 2017-04-21 | 2025-03-01 | Implicit Bioscience Ltd | CD14 antagonist antibodies for the treatment of neurodegenerative diseases |
| CN113842449B (zh) * | 2021-09-08 | 2024-02-23 | 乐卫东 | 枸杞糖肽在制备预防和/或治疗肌萎缩侧索硬化的药物中的应用 |
| WO2025049671A1 (en) * | 2023-08-30 | 2025-03-06 | The Methodist Hospital | Markers of amyotrophic lateral sclerosis survival and uses thereof |
| WO2025058005A1 (ja) * | 2023-09-15 | 2025-03-20 | 国立大学法人徳島大学 | 筋萎縮性側索硬化症（ａｌｓ）と関連するバイオマーカー |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110086894A1 (en) | 2009-10-06 | 2011-04-14 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Biomarkers for the diagnosis of als |
| US20120058498A1 (en) | 2009-03-11 | 2012-03-08 | Anthony Marotta | Compositions and Methods for Characterizing Arthritic Conditions |
| JP2013522589A (ja) | 2010-03-10 | 2013-06-13 | イエダ リサーチ アンド ディベロップメント カンパニー リミテッド | Ａｌｓの早期診断およびａｌｓ進行のための細胞性血液マーカー |
| WO2017103001A2 (en) | 2015-12-16 | 2017-06-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Diagnostic markers of immunosenescence and methods for determining the susceptibility to nosocomial infections |
| JP2020517740A (ja) | 2017-04-21 | 2020-06-18 | インプリシット バイオサイエンス プロプライアタリー リミティド | 神経変性疾患を治療するためのｃｄ１４アンタゴニスト抗体 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4018653A (en) | 1971-10-29 | 1977-04-19 | U.S. Packaging Corporation | Instrument for the detection of Neisseria gonorrhoeae without culture |
| US4016043A (en) | 1975-09-04 | 1977-04-05 | Akzona Incorporated | Enzymatic immunological method for the determination of antigens and antibodies |
| US4424279A (en) | 1982-08-12 | 1984-01-03 | Quidel | Rapid plunger immunoassay method and apparatus |
| ES2083152T3 (es) * | 1990-11-30 | 1996-04-01 | Monoclonetics Int | Metodos para el diagnostico de dolores cronicos lumbares y cervicales. |
| US5820858A (en) | 1993-05-28 | 1998-10-13 | The Scripps Research Institute | Methods and compositions for inhibiting CD14 mediated cell activation |
| CA2319828A1 (en) | 1998-01-29 | 1999-08-05 | Miller, Samuel | High density arrays for proteome analysis and methods and compositions therefor |
| US6406921B1 (en) | 1998-07-14 | 2002-06-18 | Zyomyx, Incorporated | Protein arrays for high-throughput screening |
| AU2001255436A1 (en) | 2000-04-17 | 2001-10-30 | Transtech Pharma | Protein expression system arrays and use in biological screening |
| GB0022978D0 (en) | 2000-09-19 | 2000-11-01 | Oxford Glycosciences Uk Ltd | Detection of peptides |
| US20050130320A1 (en) | 2000-11-09 | 2005-06-16 | George Shaji. T. | Method for identifying the proteome of cells using an antibody library microarray |
| AU2001290315A1 (en) | 2000-11-22 | 2002-06-03 | Mochida Pharmaceutical Co., Ltd. | Anti-cd14 monoclonal antibody having effect of inhibiting cd14/tlr binding |
| US6800453B2 (en) | 2001-01-23 | 2004-10-05 | President And Fellows Of Harvard College | Nucleic-acid programmable protein arrays |
| WO2003062444A2 (en) | 2001-11-13 | 2003-07-31 | Emory University | Array systems and methods |
| JP2005510524A (ja) * | 2001-11-16 | 2005-04-21 | アルス・セラピー・デベロツプメント・フアンデーシヨン・インコーポレーテツド | ポリアミン経路の調節による神経変性障害の治療 |
| AU2003224674A1 (en) | 2002-03-11 | 2003-09-29 | Hk Pharmaceuticals, Inc. | Compounds and methods for analyzing the proteome |
| WO2005020784A2 (en) * | 2003-05-23 | 2005-03-10 | Mount Sinai School Of Medicine Of New York University | Surrogate cell gene expression signatures for evaluating the physical state of a subject |
| ES2406266T3 (es) * | 2004-05-11 | 2013-06-06 | Mochida Pharmaceutical Co., Ltd. | Antígeno CD14 soluble novedoso |
| BR112012002333A2 (pt) * | 2009-08-06 | 2017-07-18 | Neuraltus Pharmaceuticals Inc | método de reduzir os efeitos colaterais e método de potencializar o efeito de um imunomodulador administrado a um sujeito que dele necessita; métodos para tratar doença associada com excesso de ativação de monócitos para macrófagos ativados, diabetes tipo ii ou complicações relacionadas, doença associada com a migração de monócitos ou macrófagos ativados, doença associada a excesso de produção de scd14 e/ou scd163 por macrófagos ativados; composto de cloreto de sódio; composição farmacêutica; método para diagnosticar uma doença relacionada com macrófagos em um sujeito; e método para determinar a eficácia do tratamento com um agente oxidante para uma doença relacionada a macrófagos em um sujeito. |
| EP2501720A2 (en) * | 2009-11-18 | 2012-09-26 | Lascco SA | Ifn inhibitors in the treatment of motoneuron diseases |
| WO2012004276A2 (en) * | 2010-07-06 | 2012-01-12 | Fondazione Telethon | Multiprotein biomarkers of amyotrophic lateral sclerosis in peripheral blood mononuclear cells, diagnostic methods and kits |
| US9506923B2 (en) * | 2011-08-12 | 2016-11-29 | Lsi Medience Corporation | Method of diagnosing surgical site infections |
| US10184151B2 (en) * | 2011-10-11 | 2019-01-22 | The Brigham And Women's Hospital, Inc. | Micrornas in neurodegenerative disorders |
| WO2014102333A1 (en) * | 2012-12-28 | 2014-07-03 | Mitsubishi Chemical Medience Corporation | Use of scd14 or its fragments or derivatives for risk stratisfaction, diagnosis and prognosis |
| EP3142674A4 (en) * | 2014-05-16 | 2018-01-17 | Neuraltus Pharmaceuticals, Inc. | Methods and compositions for treatment of macrophage-related disorders |
| WO2016083374A1 (en) * | 2014-11-25 | 2016-06-02 | F. Hoffmann-La Roche Ag | Biomarkers of fast progression of chronic kidney disease |
| HK1250012A1 (zh) * | 2015-04-02 | 2018-11-23 | The Methodist Hospital System | 基於多孔硅微粒的癌症疫苗及增强抗肿瘤免疫的方法 |
| WO2017147378A1 (en) * | 2016-02-25 | 2017-08-31 | The Trustees Of Columbia University In The City Of New York | Systemic immune activation and biomarkers of nonceliac wheat/gluten sensitivity |
| AU2024238511A1 (en) * | 2023-03-21 | 2025-10-02 | Coya Therapeutics, Inc. | Biomarkers of amyotrophic lateral sclerosis and uses thereof |
-
2019
- 2019-05-10 AU AU2019264996A patent/AU2019264996A1/en not_active Abandoned
- 2019-05-10 JP JP2020563696A patent/JP7371019B2/ja active Active
- 2019-05-10 WO PCT/US2019/031858 patent/WO2019217916A1/en not_active Ceased
- 2019-05-10 KR KR1020207034330A patent/KR20210014109A/ko not_active Ceased
- 2019-05-10 IL IL278616A patent/IL278616B2/en unknown
- 2019-05-10 EP EP19726841.0A patent/EP3791188A1/en not_active Withdrawn
- 2019-05-10 US US17/054,131 patent/US20210231686A1/en not_active Abandoned
- 2019-05-10 CN CN201980045566.7A patent/CN112424608A/zh active Pending
-
2023
- 2023-10-18 JP JP2023179310A patent/JP2023181255A/ja active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120058498A1 (en) | 2009-03-11 | 2012-03-08 | Anthony Marotta | Compositions and Methods for Characterizing Arthritic Conditions |
| US20110086894A1 (en) | 2009-10-06 | 2011-04-14 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Biomarkers for the diagnosis of als |
| JP2013522589A (ja) | 2010-03-10 | 2013-06-13 | イエダ リサーチ アンド ディベロップメント カンパニー リミテッド | Ａｌｓの早期診断およびａｌｓ進行のための細胞性血液マーカー |
| WO2017103001A2 (en) | 2015-12-16 | 2017-06-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Diagnostic markers of immunosenescence and methods for determining the susceptibility to nosocomial infections |
| JP2020517740A (ja) | 2017-04-21 | 2020-06-18 | インプリシット バイオサイエンス プロプライアタリー リミティド | 神経変性疾患を治療するためのｃｄ１４アンタゴニスト抗体 |
Non-Patent Citations (14)
| Title |
|---|
| Anita C. E. Vreugdenhil，Lipopolysaccharide Binding Protein and Serum Amyloid A Secretion by Human Intestinal Epithelial Cells During the Acute Phase Response，J Immunol，1999年09月01日，Vol.163 No.5，Page.2792-2798 |
| Benjamin J. Murdock，Correlation of Peripheral Immunity With Rapid Amyotrophic Lateral Sclerosis Progression，JAMA Neurol，2017年09月25日，Vol.74 No.12，Page.1446-1454 |
| Carey L. Shive，Soluble CD14 is a nonspecific marker of monocyte activation，AIDS，2015年，Vol.29，Page.1263-1265 |
| Christian Lunetta，Serum C-Reactive Protein as a Prognostic Biomarker in Amyotrophic Lateral Sclerosis，JAMA Neurol，2017年06月01日，Vol.74 No.6，Page.660-667 |
| David R. Beers，Elevated acute phase proteins reflect peripheral inflammation and disease severity in patients with amyotrophic lateral sclerosis，Scientific Reports，2020年11月17日，Vol.10 No.1，Page.15295 |
| David R. Beers，Tregs Attenuate Peripheral Oxidative Stress and Acute Phase Proteins in ALS，ANN NEUROL，2022年，Vol.92，Page.195-200 |
| H. Blasco，Further development of biomarkers in amyotrophic lateral sclerosis，EXPERT REVIEW OF MOLECULAR DIAGNOSTICS，2016年06月20日，Vol.60 No.8，Page.853-868 |
| Jason Thonhoff，Plasmapheresis Improves the Suppressive Function of Regulatory T Cells in Patients with Fast-Progressing Amyotrophic Lateral Sclerosis (P3.183)，Neurology，2016年04月04日，Vol.86 No.16 Supplement，Paeg.P3.183 |
| Keizman D，Low-grade systemic inflammation in patients with amyotrophic lateral sclerosis，Acta Neurol Scand，2009年，Vol.119，Page.383-389 |
| Michael P. Gustafson，Comprehensive immune profiling reveals substantial immune system alterations in a subset of patients with amyotrophic lateral sclerosis，PLOS ONE，2017年07月25日，Vol.12 No.7，Page.e0182002 |
| S.D. Sussmuth，CSF glial markers correlate with survival in amyotrophic lateral sclerosis，Neurology，Vol.74 No.12，2010年03月23日，Page.982-987 |
| Sylvette Bas，CD14 Is an Acute-Phase Protein，The Journal of Immunology，2004年04月01日，Vol.172 No.7，Page.4470-4479 |
| Weihua Zhao，Potential Immune Biomarkers for Disease Progression in ALS (P5.040)，Neurology，2016年04月05日，Vol.86 No.16 Supplement，Page.P5.040 |
| Yang Hu，Increased peripheral blood inflammatory cytokine levels in amyotrophic lateral sclerosis: a meta-analysis study，Scientific Reports，2017年08月22日，Vol.7，Page.9094 |
Also Published As
| Publication number | Publication date |
|---|---|
| IL278616B2 (en) | 2025-02-01 |
| IL278616A (https=) | 2021-01-31 |
| JP2021523375A (ja) | 2021-09-02 |
| US20210231686A1 (en) | 2021-07-29 |
| IL278616B1 (en) | 2024-10-01 |
| CN112424608A (zh) | 2021-02-26 |
| EP3791188A1 (en) | 2021-03-17 |
| WO2019217916A1 (en) | 2019-11-14 |
| JP2023181255A (ja) | 2023-12-21 |
| AU2019264996A1 (en) | 2020-11-26 |
| KR20210014109A (ko) | 2021-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023181255A (ja) | 疾病の予後と管理のための方法 | |
| US10877049B2 (en) | Biomarkers for diagnosis and management of neuro-immunological diseases | |
| Calissano et al. | Intraclonal complexity in chronic lymphocytic leukemia: fractions enriched in recently born/divided and older/quiescent cells | |
| EP2271672A2 (en) | Immunoglobulin and/or toll-like receptor proteins associated with myelogenous haematological proliferative disorders and uses thereof | |
| JP6868655B2 (ja) | Ｃｄ６結合パートナーの使用およびそれに基づく方法 | |
| WO2009120341A2 (en) | Biomarkers for predicting response to immunosuppressive therapy | |
| US11262358B2 (en) | Infiltrating immune cell proportions predict anti-TNF response in colon biopsies | |
| US20240150836A1 (en) | Methods of predicting and treating immunotherapy toxicity based on immune cell populations | |
| AU2020222262A1 (en) | Type I interferon-mediated disorders | |
| CN115104029A (zh) | 用于检测和监测全身性炎症的非侵入性测定法 | |
| EP2795337B1 (en) | Screening methods to identify compounds useful in the prevention and/or treatment of inflammatory conditions | |
| EP4499875B1 (en) | Biomarkers of il7r modulator activity | |
| JP2022526131A (ja) | 肝細胞癌診断用バイオマーカーセレブロンと、これに特異的な新規なモノクローナル抗体 | |
| Class et al. | Patent application title: SCREENING METHODS TO IDENTIFY COMPOUNDS USEFUL IN THE PREVENTION AND/OR TREATMENT OF INFLAMMATORY CONDITIONS Inventors: Reginald Christophe Xavier Brys (Mechelen, BE) Reginald Christophe Xavier Brys (Mechelen, BE) Sonia Dupont (Romainville, FR) Assignees: GALAPAGOS NV |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220510 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220510 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230412 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230509 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230809 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230919 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231018 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7371019 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |